Sugi Predict

Sugi Predict / Targets / NPC1L1

NPC1L1

NPC1-like intracellular cholesterol transporter 1 · Q9UHC9 · NPC1L1 on Sugi Atlas →

33,950 patent compounds predicted against NPC1L1, 24,701 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL318945 SCHEMBL318945 0.47 16/20
SCHEMBL319273 SCHEMBL319273 0.51 14/20
SCHEMBL318756 SCHEMBL318756 0.61 13/20
SCHEMBL319005 SCHEMBL319005 0.57 13/20
SCHEMBL320092 SCHEMBL320092 0.57 13/20
SCHEMBL319383 SCHEMBL319383 0.55 13/20
SCHEMBL319932 SCHEMBL319932 0.55 13/20
SCHEMBL319028 SCHEMBL319028 0.53 13/20
SCHEMBL318404 SCHEMBL318404 0.53 13/20
SCHEMBL318405 SCHEMBL318405 0.53 13/20
SCHEMBL318942 SCHEMBL318942 0.53 13/20
SCHEMBL318940 SCHEMBL318940 0.52 13/20
SCHEMBL318941 SCHEMBL318941 0.52 13/20
SCHEMBL318160 SCHEMBL318160 0.51 13/20
SCHEMBL318225 SCHEMBL318225 0.59 12/20
SCHEMBL452269 SCHEMBL452269 0.57 12/20
SCHEMBL452270 SCHEMBL452270 0.57 12/20
SCHEMBL318110 SCHEMBL318110 0.55 12/20
SCHEMBL452384 SCHEMBL452384 0.54 12/20
SCHEMBL452385 SCHEMBL452385 0.54 12/20

Clinical trials — most relevant to NPC1L1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons PHASE4COMPLETED
Safety and Efficacy of Miglustat in Chinese NPC Patients PHASE4COMPLETED
Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2) PHASE4UNKNOWN
Evaluation of Statin Mechanism Preventing Cardiovascular Disease by Post-hoc Analysis of Treating to New Targets Study PHASE4COMPLETED
Effect of Evolocumab on Vascular Function PHASE4COMPLETED
LDL Receptor Under Ezetimibe and Simvastatin PHASE4COMPLETED
Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1 PHASE1/PHASE2COMPLETED
Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine PHASE1/PHASE2COMPLETED
Phase I/II Study of Hydroxychloroquine With Itraconazole With Biochemically Recurrent Prostate Cancer PHASE1/PHASE2COMPLETED
Smith-Lemli-Opitz Syndrome and Cholic Acid PHASE1/PHASE2COMPLETED
Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C PHASE1/PHASE2COMPLETED
Safety and Efficacy of Intravenous Trappsol Cyclo (HPBCD) in Niemann-Pick Type C Patients PHASE1/PHASE2COMPLETED
Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease PHASE1COMPLETED
Bioavailability of Paracetamol, Amoxicillin and Talinolol Before, Immediately and One Year After Gastric Bypass Operation PHASE1COMPLETED
Study of Inborn Errors of Cholesterol Synthesis and Related Disorders nanCOMPLETED
Plant Stanols and Gene Expression Profile nanCOMPLETED
The Influence of Food Matrix Delivery System on the Bioavailability of Vitamin D3 nanCOMPLETED
Effect of Simvastatin and Ezetimibe on Lipid and Inflammation nanCOMPLETED
Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C nanRECRUITING
Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health nanUNKNOWN
Induced Pluripotent Stem Cells for Niemann Pick Disease nanCOMPLETED
Biomarker for Niemann Pick Type C Disease (BioNPC) nanWITHDRAWN
Normal Pressure Hydrocephalus Biomarkers Investigation nanUNKNOWN
Impact of Optimal Pharmacotherapy on Lipid Profile and Qualitative Features of Atherosclerotic Plaques nanUNKNOWN
The Genetic, Protein, and Lipid Basis of Variation in Cholesterol Efflux nanCOMPLETED
Impact Of Choline in Patients With NAFLD nanUNKNOWN
Effect of High Stanol Ester Dose on Serum Lipids, Carotenoids and Fat-soluble Vitamins nanCOMPLETED
The Effect of Dietary Sitosterol on Blood Sugar and Cholesterol nanCOMPLETED
A Long-Term Study of Cholesterol Supplements for Smith-Lemli-Opitz Syndrome nanWITHDRAWN
Statin Therapy and COVID-19 Infection nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a NPC1L1 binder may also engage these)

ProteinNameSimilarity
Q6T3U3 — 0.998 Q6T3U3 →
Q6T3U4 — 0.993 Q6T3U4 →
Q8CFX1 — 0.975 Q8CFX1 →
Q7TNJ2 — 0.974 Q7TNJ2 →
NPC1 NPC intracellular cholesterol transporter 1 0.974 landscape →
P51839 — 0.973 P51839 →
Q91V24 — 0.972 Q91V24 →
P18502 — 0.972 P18502 →
ITGB4 Integrin beta-4 0.972 landscape →
Q8R2R1 — 0.972 Q8R2R1 →
Q8IZY2 — 0.971 Q8IZY2 →
Q6DYE8 — 0.971 Q6DYE8 →
P56941 — 0.971 P56941 →
Q24760 — 0.970 Q24760 →
Q9ES45 — 0.970 Q9ES45 →
Q6P1J0 — 0.970 Q6P1J0 →
P51840 — 0.970 P51840 →
NCSTN Nicastrin 0.970 landscape →
O95479 — 0.970 O95479 →
Q5T197 — 0.970 Q5T197 →
Q6AYF4 — 0.969 Q6AYF4 →
Q9Y6A1 — 0.969 Q9Y6A1 →
P57716 — 0.969 P57716 →
Q13683 — 0.969 Q13683 →
A2A863 — 0.969 A2A863 →
F1QF89 — 0.969 F1QF89 →
Q9CTG6 — 0.969 Q9CTG6 →
P18537 — 0.969 P18537 →
Q62470 — 0.968 Q62470 →
ITGB7 Integrin beta-7 0.968 landscape →